
Marju Orho-Melander
Professor

Characterization of the human skeletal muscle glycogen synthase gene (GYS1) promoter.
Author
Summary, in English
Methods Seven promoter fragments were expressed in C2C12 myoblasts and myotubes and in HEK293 cells, and the luciferase assay was used to determine transcriptional activity.
Results The highest luciferase activity, 350-fold of the promoterless vector, was obtained with nucleotides -692 to +59 in myotubes (P < 0·001), while the nucleotides -250 to +59 provided the highest, 45-fold, activity in the HEK293 cells (P < 0·001). Longer promoter constructs (nucleotides -971, -1707 and -2158 to +59, respectively) had low promoter activity in both cell types. Forskolin treatment for 24 h resulted in approximately 30% decreased promoter activity in myotubes (P < 0·05). Insulin treatment for 0·5-3 h did not increase GYS1 promoter activity; instead the activity was slightly but significantly decreased after 24 h in myotubes (P < 0·005).
Conclusions From our results we conclude that basal GYS1 promoter activity is obtained from the first 250 nucleotides of the promoter, while the nucleotides -692 to -544 seem to be responsible for muscle-specific expression, and nucleotides -971 to -692 for negative regulation. In myotubes, the GYS1 promoter was sensitive to negative regulation by forskolin, whereas insulin did not increase GYS1 transcription.
Department/s
- Genomics, Diabetes and Endocrinology
- Department of Clinical Sciences, Malmö
Publishing year
2004
Language
English
Pages
113-121
Publication/Series
European Journal of Clinical Investigation
Volume
34
Issue
2
Full text
- Available as PDF - 322 kB
- Download statistics
Links
Document type
Journal article
Publisher
Wiley-Blackwell
Topic
- Endocrinology and Diabetes
Status
Published
Research group
- Genomics, Diabetes and Endocrinology
ISBN/ISSN/Other
- ISSN: 0014-2972